<DOC>
	<DOCNO>NCT00337246</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , cyclophosphamide , mitoxantrone , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving combination chemotherapy together rituximab may kill cancer cell . It yet know whether give combination chemotherapy together rituximab effective combination chemotherapy alone treat chronic lymphocytic leukemia . PURPOSE : This randomized phase II trial study well give combination chemotherapy without rituximab work treat patient previously treat chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Patients With Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess efficacy safety fludarabine , cyclophosphamide , mitoxantrone hydrochloride without rituximab patient previously treat chronic lymphocytic leukemia . - Determine overall response rate , define complete partial remission , patient . Secondary - Determine proportion patient undetectable minimal residual disease . - Determine 2-year progression-free survival patient . - Determine 2-year overall survival patient . - Determine toxicity regimen . OUTLINE : This randomize , control , open-label , parallel group , multicenter study . Patients stratify accord prior treatment fludarabine ( refractory v refractory naive ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral fludarabine* oral cyclophosphamide* day 1-5 mitoxantrone hydrochloride IV day 1 . - Arm II : Patients receive fludarabine* , cyclophosphamide* , mitoxantrone hydrochloride arm I . Patients also receive rituximab IV day 1 . NOTE : *If oral regimen tolerate , patient may receive fludarabine IV cyclophosphamide IV day 1-3 . Treatment arm repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 56 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia require therapy Previously treat ≥ 1 chemotherapeutic regimen PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 12 week Creatinine clearance ≥ 30 mL/min Not pregnant nursing Negative pregnancy test Fertile female patient must use effective contraception 4 week , , 6 month completion study treatment Fertile male patient must use effective contraception 6 month completion study treatment No history anaphylaxis exposure rat mousederived complementarydetermining region ( CDR ) graft humanized monoclonal antibody No toxicity attributable purine analogue ( e.g. , autoimmune hemolytic anemia , neurological toxicity , allergy ) No active infection No severe ( particularly cardiac pulmonary ) diseases mental disorder would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior fludarabine ( purine analogue ) combine cyclophosphamide mitoxantrone hydrochloride No prior rituximab , either alone combination chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>